Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 and Adebrelimab vs Gemcitabine and Cisplatin/Carboplatin in Urothelial Carcinoma
NCT07393542Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102, adebrelimab in urothelial carcinoma (UC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
SHR-A2102adebrelimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07393542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393542.